Sam Scott, PhD

CGM & Real-World Evidence Scientist | Type 1 Diabetes & Exercise | Founder · Author · Scientific Advisor | Ex-Team Novo Nordisk

Locarno, Ticino, Switzerland

About

Most people recognise the value of continuous glucose monitoring (CGM) data. Few know how to turn it into clinical evidence that changes practice. That’s the gap I address. I’m a scientist, founder, and author working where continuous glucose monitoring, wearable technology, and metabolic health meet, with a particular focus on type 1 diabetes and exercise. My work covers the entire process: designing studies, collecting data, publishing findings, and turning them into practical tools for product teams, clinicians, or athletes. Track record: - Lead author of international consensus guidelines on type 1 diabetes and exercise - Published in leading diabetes and physiology journals, including The Lancet Diabetes & Endocrinology, Diabetes Care, and others - Created Enhance-d, a digital health platform used in over 60 countries, generating one of the world's largest datasets on diabetes and lifestyle - Led real-world evidence research at Team Novo Nordisk, the world’s first all-diabetes professional sports team - Authored Empowered: The Science of Exercise with Type 1 Diabetes, a practitioner’s guide based on a decade of research I write and speak regularly about CGM science, real-world evidence, and the future of metabolic health technology. If that interests you, follow along. If you’re building or scaling in the fields of CGM, wearables, or metabolic health and need a scientific advisor, collaborator, or strategic voice, get in touch.

Experience

  • Chief Executive Officer at Enhance-d
    Oct 2022 - Present · 3 yrs 9 mos

    Built and scaled a digital health platform deployed in 60+ countries by leading product strategy, international clinical partnerships, and evidence-based positioning, generating one of the largest real-world CGM datasets in type 1 diabetes and exercise globally. Authored Empowered: The Science of Exercise with Type 1 Diabetes by synthesising a decade of peer-reviewed research into a practitioner-facing guide, establishing Enhance-d as the authoritative voice at the intersection of CGM science and exercise medicine.

  • Advisor on the Exercise Physiology interest group leadership team at American Diabetes Association
    May 2024 - Present · 2 yrs 2 mos

  • Health Transformer at StartUp Health
    Jan 2023 - Present · 3 yrs 6 mos

  • Head Of Research at Team Novo Nordisk
    Aug 2019 - Mar 2023 · 3 yrs 8 mos

    Led scientific strategy and evidence generation for the world’s first all-diabetes professional sports team, translating metabolic research into applied performance and healthcare insights. Designed and led field-based studies integrating CGM and wearable technologies, resulting in publications in top-tier journals, including The Lancet Diabetes & Endocrinology and Diabetes Care. Developed evidence-based metabolic and performance strategies for professional athletes with Type 1 diabetes, improving decision-making around glucose management and training. Presented research findings and strategic recommendations directly to senior stakeholders at Novo Nordisk, supporting broader diabetes innovation discussions. Contributed to international consensus guidance on exercise and Type 1 diabetes adopted by major diabetes organisations.

  • Advanced Postdoctoral Research Fellow at University of Bern
    Aug 2019 - May 2022 · 2 yrs 10 mos

    Led the Exercise & Diabetes Research Group, supervising PhD and MSc researchers while designing clinical trials integrating CGM, wearable technology, and digital health tools, producing peer-reviewed outputs in high-impact journals. • Secured external research funding as Principal Investigator, enabling independent clinical research at the intersection of exercise physiology, glucose regulation, and metabolic health. • Collaborated with clinicians and industry partners to translate research findings into evidence-based exercise guidance for people with type 1 diabetes, contributing to the evolving clinical framework adopted by international diabetes societies.